

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – New Programs: Docetaxel for Esophagogastric Adenocarcinoma, Cisplatin and Capecitabine for Gastric Cancer; Drug Update: Shortage of BCG; Dose-Banding of Infusional Fluorouracil
- **Cancer Drug Manual** – **Revised:** Bendamustine, Crizotinib, Dactinomycin Etoposide, Filgrastim, Rituximab
- **Benefit Drug List** – Docetaxel for Esophagogastric Adenocarcinoma, Cisplatin and Capecitabine for Gastric Cancer
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – **New:** GIAVDOC, GIGAVCC, SAAJAP, SAAVAP; **Revised:** CNAJZRT, GOOVDOC, GOOVETO, GOOVGEM, GOOVLDOX, GOOVLDC, GOOVTAX3, GOOVTOP, GOOVVIN, UGUPENZ
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAM

The Provincial Systemic Therapy Program has approved the following programs effective 01 September 2014:

Single Agent Docetaxel for Metastatic Esophagogastric Adenocarcinoma (GIAVDOC) – In a phase III trial involving 168 patients and compared to best supportive care, docetaxel was associated with improved overall survival (5.2 vs. 3.2 months) as a second line therapy after progression on platinum-based chemotherapy (*Ford et al. Lancet Oncol 2014*)

Cisplatin and Capecitabine for Metastatic or Locally Advanced Gastric Cancer (GIGAVCC) – In a phase III trial involving 316 patients, this combination regimen was associated with non-inferior efficacy compared to cisplatin-fluorouracil chemotherapy (*Kang et al. Ann Oncol 2009*). This regimen should also offer a less toxic option to the triple combination of epirubicin, cisplatin and capecitabine (GIGECC).

DRUG UPDATE

Shortage of Bacillus Calmette-Guérin (BCG) Vaccine – Merck, the manufacturer of OncoTICE® (BCG, Strain TICE®), is currently experiencing supplies issue. Therefore, OncoTICE® can only be obtained from Merck on allocation on a patient by patient basis. Use of BCG therapy may be prioritized to patients with superficial transitional cell bladder cancer and a high risk of recurrence or progression to invasive disease (any high grade tumour including carcinoma in situ (CIS), and any T1 tumour).

EDITOR'S CHOICE

DOSE BANDING OF INFUSIONAL FLUOROURACIL FOR GASTROINTESTINAL (GI) PROTOCOLS

“Save the Date – Dose Banding of Infusional Fluorouracil Effective 1 October” – The BC Cancer Agency (BCCA) is moving towards the implementation of dose banding for fluorouracil administered by INFUSORS® as of 1 October 2014. This initiative will affect GI protocols with a 46-hour infusional fluorouracil treatment:

GIAJFFOX	GIFOLFIRI
GIRAJFFIX	GIGOLFIRI
GIAJFL	UGIFFOXB
GIAVFL	GIFOLFOX
GIFFIRB	UGIFIRINOX

The dose banding of infusional fluorouracil is being implemented to improve patient safety and the efficiency of the drug preparation process. Dose banding involves the rounding of an individually calculated dose to a predetermined standard dose. Currently, BCCA already uses a form of standardized dosing with the dispensing of oral capecitabine.

With infusional fluorouracil, physicians will continue to calculate an individual patient's dose. If the dose is within the range of 3000-5500 mg, Pharmacy will substitute with the standardized dose and provide the drug in an infusional device that delivers the dose in a 230 mL volume at 5 mL/hour. Doses outside this range will continued to be prepared individually with the exact dose by Pharmacy.

Video linked presentations for BCCA Pharmacy and Nursing staff education will be provided at 12:30-13:00 on 18 and 25 of September by Tonya Ng, Provincial Medication Safety Coordinator, and Nancy Coady, GI Tumour Group Pharmacist.

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key revisions are listed below:

Bendamustine Monograph:

- Dosage in renal failure and dialysis has been updated.

Crizotinib Monograph and Auxiliary Label List:

Management of interactions with acid suppression drugs has been revised:

- Adjustment for starting dose of crizotinib is not necessary
- Auxiliary label for spacing the drug administration times with antacids is not needed

Dactinomycin Monograph and Chemotherapy Preparation and Stability Chart:

- A new product and supplier have been added, plus clarification of compatible infusion solutions

Etoposide Monograph and Chemotherapy Preparation and Stability Chart:

- Updated to include recommendation to filter during routine administration as per recent BCCA Provincial Pharmacy Directive III-50-4.

CANCER DRUG MANUAL

Filgrastim Monograph and Chemotherapy Preparation and Stability Chart:

- *Special Precautions* – updated to include avoidance of concurrent radiotherapy, cautions in patients with sickle cell disease.
- *Side Effects* – addition of sickle cell crisis, cardiac events, pseudogout, acute respiratory syndrome and alveolar hemorrhage, cutaneous vasculitis, and capillary leak syndrome, plus updated paragraphs for hypersensitivity and osteoporosis.
- *Supply and Storage* – updated storage information, including accidental exposure to freezing or room temperature.

Rituximab Monograph and Chemotherapy Preparation and Stability Chart:

- The stability of diluted solution at room temperature has been revised, plus clarification of storage information when it is removed from the fridge.

BENEFIT DRUG LIST

NEW PROGRAMS

The following programs has been added to the [Benefit Drug List](#) effective 01 September 2014:

Protocol Title	Protocol Code	Benefit Status
Palliative Treatment of Metastatic Esophagogastric Adenocarcinoma with <i>DOCEtaxel</i>	GIAVDOC	Class I
Palliative Therapy for Metastatic or Locally Advanced Gastric Cancer using <i>CISplatin</i> and <i>Capecitabine</i>	GIGAVCC	Class II

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indications Request) approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GIAVDOC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Palliative Treatment of Metastatic Esophagogastric Adenocarcinoma with <i>DOCEtaxel</i>
GIGAVCC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy for Metastatic or Locally Advanced Gastric Cancer using <i>CISplatin</i> and <i>Capecitabine</i>
SAAJAP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Therapy for Osteosarcoma Using DOXOrubicin and CISplatin
SAAVAP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Therapy of Advanced Osteosarcoma Using DOXOrubicin and CISplatin

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
CNAJZRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation
GOOVD0C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and exclusions clarified, contact physician updated</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using DOCEtaxel
GOOVETO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and exclusions clarified</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using Etoposide
GOOVGEM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and exclusions clarified</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using Gemcitabine
GOOVLDOX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and exclusions clarified</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using DOXOrubicin liposomal (Pegylated)
GOOVPLDC	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Typo in toxicities management corrected</i>	Second line treatment for Epithelial Ovarian Cancer Relapsing after primary treatment using Pegylated Liposomal DOXOrubicin (PLD) and CARBOplatin
GOOVTAX3	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and exclusions clarified, contact physician updated</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using PACLitaxel
GOOVTOP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and exclusions clarified</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using Topotecan
GOOVVIN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and exclusions clarified</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using Vinorelbine
UGUPENZ	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Blood pressure monitoring clarified</i>	Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Enzalutamide

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
Cancer Drug Manual	www.bccancer.bc.ca/cdm
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
CON Pharmacy Educators	www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604.877.6000 x 673028		sally.waignein@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Mário de Lemos, PharmD, MSc (Oncol) (Editor)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN
 Rob Watt, BSc (Pharm)